MD Biosciences has expanded its preclinical contract research services with a new suite of in vivo and in vitro cancer models. The company’s oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression.
 
The services include both syngeneic and xenograft models with readouts for immune cell distribution, biomarkers, etc., end time-point primary/metastatic tumor evaluation, tumor tissue-specific cellular analysis using intravascular staining (cells: epithelial, endothelial, immune etc.), biomarker analysis and histological grading and evaluation of tumor specific tissue.
 
“Our onco-immunology research team is comprised of skilled scientists with deep-rooted expertise in a highly complex field,” said Eddie Moradian, MD Biosciences chief executive officer. “We at MD Biosciences are excited to bring our high level of expertise and our novel models to assist sponsors and partners in reaching their programs’ developmental goals. This new suite of capabilities compliments our existing, best-in-class services in other disease areas.”